ReviewBioMed research international2018
Onco-Multi-OMICS Approach: A New Frontier in Cancer Research.
Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06108310 (ATTRACT - ArTificial inTelligence-based RAdiogenomics in Colon Tumors), which is not on this map. Cited by 172 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ATTRACT - ArTificial inTelligence-based RAdiogenomics in Colon Tumors
Who cites it
172 citing papers in PubMed, 2 syntheses or guidelines pooled it, 319 citations in OpenAlex.
- Machine learning-based analysis of cancer cell-derived vesicular proteins revealed significant tumor-specificity and predictive potential of extracellular vesicles for cell invasion and proliferation - A meta-analysis.Cell communication and signaling : CCS · 2023Pooled it
- Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens.Archives of toxicology · 2020Guideline
- OmicsTransformer: self-supervised masked consistency and uncertainty-aware fusion for robust multi-omics prediction.Bioinformatics (Oxford, England) · 2026Article
- Target identification and assessment in the era of AI.Nature reviews. Drug discovery · 2026Review
- Proteomic Profiling of PTEN Inhibition on Periodontal Ligament Stem Cells.International dental journal · 2026Article
- Drug repositioning in metastatic prostate cancer based on protein- protein interaction network: Computational and in vitro analysis.Biochemistry and biophysics reports · 2026Article
- Article
- A unified framework for correcting batch effects and integrating multi-omics data.Scientific reports · 2026Article
- AI based multiomics integration for cancer diagnosis and prognosis.Journal, genetic engineering & biotechnology · 2026Article
- Experimental Validation of miR-4443, miR-572, and miR-150-5p in Serum and Tissue of Breast Cancer Patients as a Potential Diagnostic Biomarker: A Study Based on Bioinformatics Prediction.Biochemical genetics · 2026Article
- Unlocking the power of extracellular vesicles: multi-omics integration for cancer biomarker discovery.Biomarker research · 2026Review
- Article
- Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation.Nature machine intelligence · 2026Article
- Multiomics Approaches for Bacteriophage-Based Biocontrol Applications: A Review of Metabolomics, Transcriptomics, and Proteomics.BioMed research international · 2026Review
- The role of MiRNA-mediated tumor microenvironment in bone metastasis from a multi-omics perspective: cross-cancer mechanisms and clinical translation.Frontiers in oncology · 2026Review
- From Radical Resection to Precision Surgery: Integrating Diagnostic Biomarkers, Radiomics-Based Predictive Models, and Perioperative Systemic Therapy in Head and Neck Oncology.Diagnostics (Basel, Switzerland) · 2025Review
- A novel statistical feature selection framework for biomarker discovery and cancer classification via multiomics integration.BMC medical research methodology · 2025Article
- A clustering-stratified cross-validation framework for validating omics survival models: application to head and neck cancer.BMC medical research methodology · 2025Article
- Decoupled contrastive multi-view clustering with adaptive false negative elimination for cancer subtyping.PLoS computational biology · 2025Article
- Review
112 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acquisition of cancer hallmarks requires molecular alterations at multiple levels including genome, epigenome, transcriptome, proteome, and metabolome. In the past decade, numerous attempts have been made to untangle the molecular mechanisms of carcinogenesis involving single OMICS approaches such as scanning the genome for cancer-specific mutations and identifying altered epigenetic-landscapes within cancer cells or by exploring the differential expression of mRNA and protein through transcriptomics and proteomics techniques, respectively. While these single-level OMICS approaches have contributed towards the identification of cancer-specific mutations, epigenetic alterations, and molecular subtyping of tumors based on gene/protein-expression, they lack the resolving-power to establish the casual relationship between molecular signatures and the phenotypic manifestation of cancer hallmarks. In contrast, the multi-OMICS approaches involving the interrogation of the cancer cells/tissues in multiple dimensions have the potential to uncover the intricate molecular mechanism underlying different phenotypic manifestations of cancer hallmarks such as metastasis and angiogenesis. Moreover, multi-OMICS approaches can be used to dissect the cellular response to chemo- or immunotherapy as well as discover molecular candidates with diagnostic/prognostic value. In this review, we focused on the applications of different multi-OMICS approaches in the field of cancer research and discussed how these approaches are shaping the field of personalized oncomedicine. We have highlighted pioneering studies from "The Cancer Genome Atlas (TCGA)" consortium encompassing integrated OMICS analysis of over 11,000 tumors from 33 most prevalent forms of cancer. Accumulation of huge cancer-specific multi-OMICS data in repositories like TCGA provides a unique opportunity for the systems biology approach to tackle the complexity of cancer cells through the unification of experimental data and computational/mathematical models. In future, systems biology based approach is likely to predict the phenotypic changes of cancer cells upon chemo-/immunotherapy treatment. This review is sought to encourage investigators to bring these different approaches together for interrogating cancer at molecular, cellular, and systems levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.